6ER-013 Analysis of biological treatments as possible therapeutic alternatives in refractory anti-tnf patients in crohn’s disease

BACKGROUND: At the moment the main treatment goals in Crohn’s desease (CD) are to induce and maintain remission, controlling inflammatory activity to keep the patient free of symptoms and avoid complications. PURPOSE: To establish whether vedolizumab and ustekinumab can be declared equivalent therap...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Donoso-Rengifo, MC, Lopez-Santamaria, J, Murillo-Izquierdo, M, Ramos, J Cordero, Rendon-Lope, L, Alegre, E
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Section 6: Education and research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535249/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.506
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars